| Gene symbol | CSF2 | Synonyms | CSF, GMCSF | Type of gene | protein-coding | |
| Chromosome | 5 | Map location | 5q31.1 | dbXrefs | Entrez:1437 MIM:138960 HGNC:HGNC:2434 Ensembl:ENSG00000164400 AllianceGenome:HGNC:2434 | |
| Gene perturbation-related omics dataset | PerturbAtlas | |||||
| Description | colony stimulating factor 2 | |||||
| Gene symbol | E2F1 | Synonyms | E2F-1, RBAP1, RBBP3, RBP3 | Type of gene | protein-coding | |
| Chromosome | 20 | Map location | 20q11.22 | dbXrefs | Entrez:1869 MIM:189971 HGNC:HGNC:3113 Ensembl:ENSG00000101412 AllianceGenome:HGNC:3113 | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
| Description | E2F transcription factor 1 | |||||
| GTO ID | GTC3967 |
| Trial ID | NCT04610671 |
| Disease | Bladder Cancer |
| Altered gene | E2F1|CSF2 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | CG0070|Cretostimogene Grenadenorepvec |
| Co-treatment | Nivolumab |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 1 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer (MIBC) |
| Year | 2020 |
| Country | United States |
| Company sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Other ID(s) | MCC-20575 |
| Vector information | |||||||||||||||
|
|||||||||||||||
| Cohort 1 | |||||||||
|
|||||||||